SCHEMBL29771950

SCHEMBL29771950

CC(C)(C)OC(=O)N[C@@H]1CCc2c(Br)cccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UCHL1 P09936 1/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
GAA P10253 1/20 0.39
KDM1A O60341 2/20 0.39
MAOB P27338 2/20 0.39
EPHX2 P34913 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
DRD2 P14416 3/20 0.37
ACHE P22303 2/20 0.37
MAOA P21397 1/20 0.37
KCNA3 P22001 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1868501 1.00 UCHL1 (0.41) UCHL1KMT2AMEN1NPC1HTT
SCHEMBL1868500 1.00 UCHL1 (0.41) UCHL1KMT2AMEN1NPC1HTT
SCHEMBL1873295 1.00 UCHL1 (0.41) UCHL1KMT2AMEN1NPC1HTT
SCHEMBL13974108 0.93 TAS1R3 (0.43) UCHL1KMT2A
SCHEMBL13974252 0.93 TAS1R3 (0.43) UCHL1KMT2A
SCHEMBL29771900 0.93 TAS1R3 (0.43) UCHL1KMT2A
SCHEMBL27877844 0.88 UCHL1 (0.40) UCHL1KMT2AMEN1NPC1HTT
SCHEMBL27894597 0.88 UCHL1 (0.40) UCHL1KMT2AMEN1NPC1HTT
SCHEMBL24619628 0.87 KDM4E (0.41) KMT2AGAAKDM1AMAOBEPHX2
SCHEMBL8187705 0.86 GAA (0.39) UCHL1KMT2AMEN1NPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220220152-A1 BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS Hepagene Therapeutics (HK) Limited (HK) 2022-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220152-A1 BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS BIRC5, BIRC2, BIRC3 UCHL1 1545/4885KMT2A 3944/4885MEN1 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.